[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

about

A Novel Computational Method for the Identification of Potential miRNA-Disease Association Based on Symmetric Non-negative Matrix Factorization and Kronecker Regularized Least Square

P2860

Q58728435-0C33CC7B-60C9-44FA-8B77-3F8F2D5D5405

P2860

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

Item

http://www.wikidata.org/entity/Q54109659

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

@en

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

@nl

type

Item

label

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

@en

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

@nl

prefLabel

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

@en

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

@nl

P1476

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

@en

P2093

Lei Liu

http://www.w3.org/2001/XMLSchema#string

Suju Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.

New driver mutations in non-small-cell lung cancer.

Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.

P304

419-424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3779/J.ISSN.1009-3419.2018.05.11

http://www.w3.org/2001/XMLSchema#string

P407

Chinese

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29764594

http://www.w3.org/2001/XMLSchema#string

P932

5999922

http://www.w3.org/2001/XMLSchema#string

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

about

P2860

P2860

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932